F-star Therapeutics, Inc. – NASDAQ:FSTX
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 14 hours
F-star Therapeutics stock price monthly change
+61.09%
month
F-star Therapeutics stock price quarterly change
+33.84%
quarter
F-star Therapeutics stock price yearly change
+145.94%
year
F-star Therapeutics key metrics
Market Cap | 156.51M |
Enterprise value | 132.72M |
P/E | -3.89 |
EV/Sales | 6.26 |
EV/EBITDA | -2.99 |
Price/Sales | 7.34 |
Price/Book | 2.73 |
PEG ratio | -0.04 |
EPS | -2.08 |
Revenue | N/A |
EBITDA | -44.12M |
Income | -44.99M |
Revenue Q/Q | 49.80% |
Revenue Y/Y | 452.72% |
Profit margin | -211.32% |
Oper. margin | -173.56% |
Gross margin | 0% |
EBIT margin | -173.56% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeF-star Therapeutics stock price history
F-star Therapeutics stock forecast
F-star Therapeutics financial statements
| Dec 2021 | 17.49M | 4.74M | 27.09% |
|---|---|---|---|
| Mar 2022 | 2.55M | -12.14M | -476.09% |
| Jun 2022 | 0 | -19.12M | |
| Sep 2022 | 1.12M | -18.46M | -1641.51% |
| 2022-08-11 | -1.32378 | -0.88 |
|---|---|---|
| 2022-11-10 | -0.89544 | -0.84 |
| 2023-03-22 | -0.39 | 0.47 |
| Dec 2021 | 123021000 | 26.16M | 21.27% |
|---|---|---|---|
| Mar 2022 | 114706000 | 26.54M | 23.14% |
| Jun 2022 | 100644000 | 29.00M | 28.82% |
| Sep 2022 | 83717000 | 26.77M | 31.99% |
| Dec 2021 | 6.78M | 0 | 1.05M |
|---|---|---|---|
| Mar 2022 | -11.61M | 0 | 1.87M |
| Jun 2022 | -16.53M | -356K | 303K |
| Sep 2022 | -16.54M | 1K | 5K |
F-star Therapeutics alternative data
| Aug 2023 | 84 |
|---|---|
| Sep 2023 | 84 |
| Oct 2023 | 84 |
| Nov 2023 | 84 |
| Dec 2023 | 84 |
| Jan 2024 | 84 |
| Feb 2024 | 84 |
| Apr 2024 | 84 |
| May 2024 | 84 |
| Jun 2024 | 84 |
| Jul 2024 | 84 |
F-star Therapeutics other data
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jul 2021 | 0 | 1054 |
| Oct 2021 | 0 | 64 |
| Nov 2021 | 0 | 64 |
| Quarter | Transcript |
|---|---|
| Q4 2021 14 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Q3 2021 14 Nov 2021 | Q3 2021 Earnings Call Transcript |
| Q2 2021 12 Aug 2021 | Q2 2021 Earnings Call Transcript |
| Q1 2021 17 May 2021 | Q1 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Eliot Richard Forster M.B.A., Ph.D. (1966) Pres, Chief Executive Officer & Director | $1,050,000 |
Ms. Darlene M. Deptula-Hicks MBA (1957) Chief Financial Officer & Treasurer | $672,380 |
F-star's Delayed Acquisition Presents A Risky Opportunity
Microsoft-Activision Deal And 20 Other Opportunities In Merger Arbitrage Space
17 Opportunities In Merger Arbitrage Space
F-star Therapeutics: A Merger Arbitrage Opportunity Expected To Close Soon
Week In Review: invoX, A Sino Biopharm Company, To Pay $161 Million To Acquire F-Star
F-star Therapeutics: Best-In-Class Tetravalent Bispecific Antibody Technology In Cancers
-
When is F-star Therapeutics's next earnings date?
Unfortunately, F-star Therapeutics's (FSTX) next earnings date is currently unknown.
-
Does F-star Therapeutics pay dividends?
No, F-star Therapeutics does not pay dividends.
-
How much money does F-star Therapeutics make?
F-star Therapeutics has a market capitalization of 156.51M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 88.05% to 21.17M US dollars. F-star Therapeutics made a loss 31.28M US dollars in net income (profit) last year or $0.47 on an earnings per share basis.
-
What is F-star Therapeutics's stock symbol?
F-star Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "FSTX".
-
What is F-star Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of F-star Therapeutics?
Shares of F-star Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are F-star Therapeutics's key executives?
F-star Therapeutics's management team includes the following people:
- Dr. Eliot Richard Forster M.B.A., Ph.D. Pres, Chief Executive Officer & Director(age: 59, pay: $1,050,000)
- Ms. Darlene M. Deptula-Hicks MBA Chief Financial Officer & Treasurer(age: 68, pay: $672,380)
-
How many employees does F-star Therapeutics have?
As Jul 2024, F-star Therapeutics employs 84 workers.
-
When F-star Therapeutics went public?
F-star Therapeutics, Inc. is publicly traded company for more then 9 years since IPO on 6 May 2016.
-
What is F-star Therapeutics's official website?
The official website for F-star Therapeutics is f-star.com.
-
How can i contact F-star Therapeutics?
F-star Therapeutics can be reached via phone at +44 1223 497400.
F-star Therapeutics company profile:
F-star Therapeutics, Inc.
f-star.comExchange:
NASDAQ
Full time employees:
84
Industry:
Biotechnology
Sector:
Healthcare
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.
Eddeva B920
Cambridge, CB22 3AT
Cambridge, CB22 3AT
CIK: 0001566373
ISIN: US30315R1077
CUSIP: 30315R107
